Free Trial
NASDAQ:ANAB

AnaptysBio (ANAB) Stock Price, News & Analysis

AnaptysBio logo
$25.74 +1.49 (+6.14%)
Closing price 04:00 PM Eastern
Extended Trading
$25.64 -0.10 (-0.41%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AnaptysBio Stock (NASDAQ:ANAB)

Key Stats

Today's Range
$23.99
$26.17
50-Day Range
$19.45
$25.74
52-Week Range
$12.21
$41.31
Volume
895,981 shs
Average Volume
648,015 shs
Market Capitalization
$756.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.38
Consensus Rating
Moderate Buy

Company Overview

AnaptysBio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

ANAB MarketRank™: 

AnaptysBio scored higher than 46% of companies evaluated by MarketBeat, and ranked 594th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AnaptysBio has only been the subject of 3 research reports in the past 90 days.

  • Read more about AnaptysBio's stock forecast and price target.
  • Earnings Growth

    Earnings for AnaptysBio are expected to grow in the coming year, from ($6.08) to ($5.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AnaptysBio is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AnaptysBio is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AnaptysBio has a P/B Ratio of 11.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AnaptysBio's valuation and earnings.
  • Percentage of Shares Shorted

    34.61% of the float of AnaptysBio has been sold short.
  • Short Interest Ratio / Days to Cover

    AnaptysBio has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in AnaptysBio has recently decreased by 0.65%, indicating that investor sentiment is improving.
  • Dividend Yield

    AnaptysBio does not currently pay a dividend.

  • Dividend Growth

    AnaptysBio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    34.61% of the float of AnaptysBio has been sold short.
  • Short Interest Ratio / Days to Cover

    AnaptysBio has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in AnaptysBio has recently decreased by 0.65%, indicating that investor sentiment is improving.
  • News Sentiment

    AnaptysBio has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for AnaptysBio this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for ANAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $493,202.00 in company stock.

  • Percentage Held by Insiders

    33.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about AnaptysBio's insider trading history.
Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Stock News Headlines

Jeff Brown: My shocking meeting in Washington, D.C.
President Trump’s “Project MAFA” After a shocking discovery in Washington D.C., Jeff Brown is putting out an urgent broadcast on Wednesday, July 16, at 8 p.m. ET to cover the president’s bold new initiative. Get a look inside Trump’s genius masterplan to create a “new” gold standard, smash the U.S. debt, and kick off a Golden Century before July 25.
Stifel Nicolaus Remains a Buy on AnaptysBio (ANAB)
See More Headlines

ANAB Stock Analysis - Frequently Asked Questions

AnaptysBio's stock was trading at $13.24 at the beginning of the year. Since then, ANAB stock has increased by 94.4% and is now trading at $25.74.

AnaptysBio, Inc. (NASDAQ:ANAB) posted its quarterly earnings results on Monday, May, 5th. The biotechnology company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.30) by $0.02. The biotechnology company had revenue of $27.77 million for the quarter, compared to analysts' expectations of $15.27 million. AnaptysBio had a negative net margin of 125.70% and a negative trailing twelve-month return on equity of 282.47%.

AnaptysBio's board approved a stock buyback plan on Monday, March 24th 2025, which allows the company to repurchase $75,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 13.1% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its stock is undervalued.

AnaptysBio (ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Moderna (MRNA) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/05/2025
Today
7/09/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ANAB
CIK
1370053
Fax
N/A
Employees
100
Year Founded
2005

Price Target and Rating

High Price Target
$90.00
Low Price Target
$20.00
Potential Upside/Downside
+65.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$145.23 million
Net Margins
-125.70%
Pretax Margin
-125.66%

Debt

Sales & Book Value

Annual Sales
$111.87 million
Price / Cash Flow
N/A
Book Value
$2.33 per share
Price / Book
11.00

Miscellaneous

Free Float
19,538,000
Market Cap
$753.01 million
Optionable
Optionable
Beta
-0.27

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ANAB) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners